All3 is treating movement around a building site as part of the construction task, rather than a separate transport problem. Its October 7 Mantis redesign brings a four-legged electric platform, a working arm and interchangeable tools into the same machine.
The company announcement describes a 135kg platform excluding its arm, designed to carry up to 100kg while walking. A narrow stance serves doorways; a wider stance supports work. All3 reports autonomous stair climbing up to 35 degrees using onboard sensing.
Mobility has to survive the transition into work
These dimensions create a useful engineering question: can the robot reach the work location while retaining enough stability to apply a tool? Carrying a load upstairs, positioning an arm and pressing into a structure impose different constraints. A successful route therefore needs to include the transition into the working stance and the path out again.
All3 reports eight successful pilot-hole fastening attempts in a repeated demonstration, and explicitly says this is not a reliability statistic. The catalogue of 68 operations describes intended scope, not completed validation across 68 tasks. The announcement also says the safety assessment is in progress.
The construction project is the next test
For a contractor, an initial evaluation should define one route and one accepted construction operation, including material placement, battery handling, setup and recovery. The denominator should include interrupted attempts and operator interventions. A machine that reaches a staircase still needs a workable procedure when the staircase or landing becomes obstructed.
All3 plans its first live construction project for early 2027. That project could connect the mobility demonstration to productive work, but only if repeated task records show acceptable quality and manageable support. The decisive next evidence is completion of a defined building operation under changing site conditions.
Sources & evidence
Sources describe the announcements and evidence available when this analysis was published. Company claims are attributed; plans and trials are not treated as sustained operation.

